Skip to main content
. 2022 Jun 21;12:853901. doi: 10.3389/fonc.2022.853901

Table 2.

Results of the base-case analysis.

LY QALY Incremental QALY Cost (RMB) Incremental cost ICER (RMB/QALY)
Sunitinib 2.83 2.13 762,572
Lenvatinib+Everolimus 2.96 2.17 0.04 795,424 32,851 776,202
Lenvatinib+Pembrolizumab 3.44 2.60 0.47 2,015,702 1,253,130 2,657,025

LY, life year; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.